Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration.

Jason S Slakter; Thomas W Bochow; Donald J D'Amico; Bethany Marks; Janice Jerdan; E Kenneth Sullivan; Stella M Robertson; Jason S Slakter; Greg Sullins; Patricia Zilliox

doi:10.1016/j.ophtha.2005.10.019

Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration.

Identifier:nobleid.org/w1/20260515/2F65DCD5

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/2F65DCD5.svg?ark=w1%2F20260515%2F2F65DCD5)](https://nobleid.org/work/w1/20260515/2F65DCD5)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration.

Identifier:nobleid.org/w1/20260515/2F65DCD5

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/2F65DCD5.svg?ark=w1%2F20260515%2F2F65DCD5)](https://nobleid.org/work/w1/20260515/2F65DCD5)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work